India’s pharma regulatory landscape is expanding beyond manufacturing compliance, with new developments targeting medicine pricing, sterile-drug quality, medical marketing, and obesity treatment.
The FDA’s latest actions bring new hope for cancer and herpes treatment while product recalls raise fresh concerns about drug safety and quality.
The Thyrocare Madurai lab strengthens regional healthcare infrastructure by expanding access to routine and specialised diagnostic testing across southern Tamil Nadu.
The most popular schizophrenia pill gets a once-a-month shot as Teva wins FDA approval for its WELTRUZA injection.
Dr Reddy's received two USFDA observations at its Andhra Pradesh facility, highlighting the importance of Indian pharma GMP compliance and manufacturing quality.
NVIDIA-backed AI is powering Iambic Therapeutics’ cancer drug pipeline as the biotech prepares for an IPO targeting a valuation of USD 806 million.
Health Minister J.P. Nadda has launched JOSH Teams to boost TB elimination in India, putting fresh focus on drug demand, supply and access.
Akums unveils a palm-free peptide skincare range targeting winter dryness, skin-barrier support and evolving consumer demand for specialized moisturization.
Drug development faces mounting safety concerns, clinical setbacks, and pressure to modernize standards. Three industry moves reveal how pharma balances risk management with faster, more efficient development.
HPV shot before pregnancy may cut preterm birth risk, adding another potential benefit to established cancer prevention.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
